Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central nervous program, conolidine modulates alternate molecular targets. A Science Innovations analyze identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://donaldr097uvx8.celticwiki.com/user